{"id":404653,"date":"2025-12-22T00:00:00","date_gmt":"2025-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0010-2025-biopharma-atopic-dermatitis-atopic-eczema-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:23:49","modified_gmt":"2026-03-31T10:23:49","slug":"dlsfim0010-2026-biopharma-atopic-dermatitis-atopic-eczema-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0010-2026-biopharma-atopic-dermatitis-atopic-eczema-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Atopic dermatitis (<abbr title=\"atopic dermatitis\">AD<\/abbr>) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of <abbr title=\"atopic dermatitis\">AD<\/abbr> treatment are to protect the skin barrier, reduce inflammation, and alleviate the itch. Topical therapies are often effective for mild disease but have suboptimal safety, tolerability, and compliance. The <abbr title=\"atopic dermatitis\">AD<\/abbr> therapy market has undergone upheaval, beginning with the 2017 launches of Sanofi \/ Regeneron\u2019s injectable biologic Dupixent and Pfizer\u2019s nonsteroidal topical cream Eucrisa. Since then, multiple agents have been approved, including oral <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors (Eli Lilly\u2019s Olumiant, AbbVie\u2019s Rinvoq, and Pfizer\u2019s Cibinqo); nonsteroidal topical agents (Shionogi\u2019s Corectim, Incyte\u2019s Opzelura, Otsuka \/ Acrotech Biopharma\u2019s Moizerto, Arcutis\u2019s Zoryve, and Organon \/ Dermavant \/ Shionogi\u2019s Vtama); an <abbr title=\"interleukin\">IL<\/abbr>-31 inhibitor (Galderma \/ Maruho\u2019s Mitchga \/ Nemluvio); and <abbr title=\"interleukin\">IL<\/abbr>-13 inhibitors (Leo Pharma\u2019s Adbry \/ Adtralza and Eli Lilly \/ Almirall\u2019s Ebglyss). This report provides a comprehensive analysis of <abbr title=\"atopic dermatitis\">AD<\/abbr> patient populations, current disease management, unmet needs, and the potential of current and emerging drugs.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the sizes of the mild, moderate, and severe <abbr title=\"atopic dermatitis\">AD<\/abbr> subpopulations, and how will they change by 2034? How well are they served by current <abbr title=\"atopic dermatitis\">AD<\/abbr> therapies?<\/li>\n<li>How have Dupixent and other biologics been incorporated into the <abbr title=\"atopic dermatitis\">AD<\/abbr> treatment algorithm? What market niches are oral <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors (e.g., Cibinqo, Rinvoq, Olumiant), topicals (e.g., Corectim, Opzelura, Moizerto, Zoryve, Vtama), and other biologics (e.g., Adbry \/ Adtralza, Mitchga \/ Nemluvio, Ebglyss) beginning to occupy?<\/li>\n<li>What therapies are in development for <abbr title=\"atopic dermatitis\">AD<\/abbr>? Of these therapies, which are best poised to achieve commercial success?<\/li>\n<li>What are the greatest unmet needs in the treatment of <abbr title=\"atopic dermatitis\">AD<\/abbr>, and to what degree will therapies in the pipeline address these needs?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n<p><b>Geography:\u00a0<\/b>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Country-specific interviews with thought-leading dermatologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed and drug-treated prevalence of <abbr title=\"atopic dermatitis\">AD<\/abbr> by country, 12-month total and diagnosed prevalence of <abbr title=\"atopic dermatitis\">AD<\/abbr> by severity<\/p>\n<p><strong>Forecast:\u00a0<\/strong>10-year, annualized, drug-level sales and patient share of key <abbr title=\"atopic dermatitis\">AD<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:\u00a0<\/strong>Coverage of key current and late-phase emerging therapies<\/p>\n","protected":false},"template":"","class_list":["post-404653","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/404653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/404653\/revisions"}],"predecessor-version":[{"id":575237,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/404653\/revisions\/575237"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=404653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}